Navigation Links
Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
Date:9/7/2012

CRANBURY, N.J., Sept. 7, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) today announced that its collaboration partner,  AstraZeneca, has decided to discontinue further development of AZD2820, one of a number of collaboration compounds in various stages of development for the treatment of obesity.  AstraZeneca remains committed to this collaboration program and to the continued advancement of melanocortin agonists for treatment of obesity.

AZD2820, a subcutaneously-administered peptide melanocortin-4 receptor partial agonist, was a clinical candidate under development by AstraZeneca from a collaborative research program with Palatin Technologies. As previously announced, a Phase I trial of AZD2820 was halted following a serious adverse event. The decision to discontinue development of the compound was made based on investigations and review conducted by AstraZeneca that followed this incident. While not confirmed, it could not be excluded that the serious adverse event was linked to AZD2820. The investigation further concluded that it is unlikely that the serious adverse event was related to melanocortin receptor activation as an approach for the treatment of obesity.

"We are pleased that the subject has fully recovered from this adverse event," said Dr. Carl Spana, President and Chief Executive Officer of Palatin. "The AZD2820 compound is part of a broader research and development collaboration with AstraZeneca. We have multiple classes of collaboration compounds in various stages of preclinical testing and AstraZeneca has informed us that they remain committed to the advancement of collaboration compounds for treatment of obesity."

Pursuant to the terms of the research collaboration and license agreement with AstraZeneca, Palatin is eligible for milestone payments upon achieving development and regulatory milestones and further payments on achievement of sales targets, in addition to royalties on sales of app
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
2. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
3. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
4. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
5. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
6. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
7. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
10. Lifeline Biotechnologies Receives Patent for Methods to Collect and Analyze Breast Thermal Data to Determine Suspect Conditions
11. Life Technologies to Present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... May 21, 2015  CytRx Corporation (NASDAQ: ... specializing in oncology, today announced positive updated results ... aldoxorubicin for the treatment of unresectable glioblastoma multiforme ... open-label, multisite trial is designed to investigate the ... whose tumors have progressed following prior treatment with ...
(Date:5/21/2015)... 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (TSX.V: ... company focused on the development of autologous cell ... the International Society for Cellular Therapy (ISCT) on ... currently in a Phase 1/2 clinical trial.  The ... from 5:30 PM to 7:00 PM local time, ...
(Date:5/20/2015)... May 20, 2015 Veracyte, Inc ... data demonstrating the ability of the company,s molecular ... from other interstitial lung diseases (ILDs) using samples ... potential to help thousands of patients avoid invasive, ... IPF diagnosis – a frequent challenge for physicians ...
(Date:5/20/2015)... May 19, 2015 Research and Markets ... "Global Cell Therapy Market Outlook 2020 " ... therapy in tissue and regenerative medicine is expected to ... options which could help in the growth of deregulated ... but they are unable to form new tissue or ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3
... 16, 2010) In one of only two studies of ... of Medicine and the Sackler School of Graduate Biomedical Sciences ... onset of some forms of eye disease and preserve vision. ... retina and found that treated mice temporarily retained more eyesight ...
... quarter 2010 revenue rose 43% year-over-year to $47.5 million,-- Second quarter 2010 net ... China BCT Reports Strong Second Quarter 2010 Results -- LIUZHOU CITY, ... ... if ...
... along with Indiana University, are excited to announce ... in the Light Microscopy Imaging Center in Bloomington, ... three dimensional, super-resolution microscopy system that more than ... This super-resolution capability is especially important to cell ...
Cached Biology Technology:Breakthrough gene therapy prevents retinal degeneration 2China BCT Reports Strong Second Quarter 2010 Results 2China BCT Reports Strong Second Quarter 2010 Results 3China BCT Reports Strong Second Quarter 2010 Results 4China BCT Reports Strong Second Quarter 2010 Results 5China BCT Reports Strong Second Quarter 2010 Results 6China BCT Reports Strong Second Quarter 2010 Results 7China BCT Reports Strong Second Quarter 2010 Results 8China BCT Reports Strong Second Quarter 2010 Results 9China BCT Reports Strong Second Quarter 2010 Results 10China BCT Reports Strong Second Quarter 2010 Results 11China BCT Reports Strong Second Quarter 2010 Results 12China BCT Reports Strong Second Quarter 2010 Results 13China BCT Reports Strong Second Quarter 2010 Results 14China BCT Reports Strong Second Quarter 2010 Results 15Applied Precision Installs New DeltaVision|OMX® Super-Resolution Imaging System in the Light Microscopy Imaging Center at Indiana University 2
(Date:5/21/2015)... According to a new ... Software, Services), by Applications (Surveillance (Airborne, Maritime, Land), ... (Military & Defense & Commercial) - Global Forecast ... is expected to grow from $7252.0 Million in ... Compound Annual Growth Rate (CAGR) of 6.6%. ...
(Date:5/20/2015)... DUBLIN , May 20, 2015 ... Markets ( http://www.researchandmarkets.com/research/h8t4x6/5year ) has announced the ... of the Global Iris Recognition Market" ... http://photos.prnewswire.com/prnh/20130307/600769) , ,This research service analyses ... across the government and commercial sectors, ...
(Date:5/19/2015)... Fingerprint Cards (FPC) has received an order for ... from one if its module partners. Deliveries are planned to ... the sensors will be used by smartphone manufacturers in ... amount to 740 MSEK to date. In addition to previously ... number of smaller orders not separately communicated amounting to more ...
Breaking Biology News(10 mins):Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
... proteins have been,viewed as the real movers and ... more than a messenger that shuttles information between ... Research,and Massachusetts Institute of Technology have discovered that ... genes--more,than one third of the genome's protein-coding regions. ...
... 29 March 2005, the Ministry of Health has reported a ... and Uige. All these cases had originated in Uige Province. ... Centers for Disease Control and Prevention (CDC), Atlanta, USA. , ... for southern Africa, the Regional Office for Africa (AFRO) and ...
... York University biologists have uncovered how the innate immune ... The findings, published as the cover study in the ... fight the virus at multiple stages--by preventing the formation ... release, which could infect other cells in the brain. ...
Cached Biology News:NYU researchers simulate molecular biological clock 2NYU Study Reveals How Brain's Immune System Fights Viral Encephalitis 2